However, HER2-targeted mAbs such as trastuzumab failed to provide clinical benefit in low-HER2-expressing (IHC2+ with ISH- or IHC1+) [78–80], which is reported to be observed in approximately 50% of breast cancer patients and other mass-forming types [81–83]. Here, ERBB2 is linked to breast carcinoma.